Drugs / QA102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04894071 | May → Nov 2021 | age-related macular degeneration | Smilebiotek Zhuhai Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05536752 | Sep 2022 → Nov 2024 | dry age related macular degeneration | Smilebiotek Zhuhai Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QA102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04894071 ↗ |
| Route | Oral | “oral administration” NCT04894071 ↗ |